This site is intended for health professionals only

AIs for advanced breast cancer

teaser

The use of third-generation aromatase inhibitors (AIs) in the treatment of advanced breast cancer in postmenopausal women shows survival benefits.

A Cochrane review compared AIs to other endocrine therapy in the treatment of advanced breast cancer in postmenopausal women, with 25 studies included in the main analysis (n=9,416).

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

The main findings were as follows. AIs were associated with a significant survival benefit over other endocrine therapies, and were not associated with any statistically significant difference in progression-free survival, clinical benefit and objective response. There were very limited data to compare one AI with a different AI, but these suggested an advantage for letrozole over anastrozole.

In the studies of AIs as first-line therapy (all versus tamoxifen), AIs were associated with statistically significant improvements in progression-free survival and clinical benefit, but not survival or objective response.

Finally, the use of an AI as second-line therapy showed a significant benefit in terms of overall survival but not for progression-free survival, clinical benefit or objective response.

 






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x